Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Adverum Biotechnlgs (ADVM)
Adverum Biotechnlgs (ADVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Adverum Biotechnlgs 100 CARDINAL WAY Redwood City CA 94063 USA

www.adverum.com P: 650-656-9323

Description:

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.

Key Statistics

Overview:

Market Capitalization, $K 82,842
Enterprise Value, $K 14,412
Shares Outstanding, K 101,027
Annual Sales, $ 0 K
Annual Net Income, $ -154,540 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -31,510 K
EBIT, $ -138,290 K
EBITDA, $ -128,600 K
60-Month Beta 0.80
% of Insider Shareholders 5.30%
% of Institutional Shareholders 70.87%
Float, K 95,673
% Float 94.70%
Short Volume Ratio 0.38

Growth:

1-Year Return 18.91%
3-Year Return -94.02%
5-Year Return -77.47%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -20.93%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.33 on 11/09/23
Next Earnings Date N/A
Earnings Per Share ttm -1.33
EPS Growth vs. Prev Qtr -6.45%
EPS Growth vs. Prev Year 17.50%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ADVM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -88.07%
Return-on-Assets % -49.38%
Profit Margin % 0.00%
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 22.89
Price/Cash Flow N/A
Price/Book 0.84
Book Value/Share 1.30
Interest Coverage -1.67
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar